Monopar Therapeutics (MNPR, Financial), in partnership with Excel Diagnostics and Nuclear Oncology Center, has received approval from the U.S. Food and Drug Administration to proceed with their Expanded Access Program (EAP). This program involves the investigational imaging agent MNPR-101-Zr and therapeutic agent MNPR-101-Lu. The EAP aims to provide patients in the United States access to these agents, which are designed to target challenging cancers, including triple-negative breast, pancreatic, and colorectal cancers.
This development marks a significant step forward in Monopar's radiopharmaceutical offerings, building on the initiation of Phase 1 clinical trials in Australia last year for MNPR-101-Zr and MNPR-101-Lu. The company expressed gratitude for the collaboration with Dr. Delpassand, which will enable these treatments to be available to patients on a compassionate use basis.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 3 analysts, the average target price for Monopar Therapeutics Inc (MNPR, Financial) is $58.00 with a high estimate of $76.00 and a low estimate of $40.00. The average target implies an upside of 68.09% from the current price of $34.51. More detailed estimate data can be found on the Monopar Therapeutics Inc (MNPR) Forecast page.
Based on the consensus recommendation from 4 brokerage firms, Monopar Therapeutics Inc's (MNPR, Financial) average brokerage recommendation is currently 2.3, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
